EWTX

Edgewise Therapeutics, Inc.

Investor Moves

InvestorPortfolio ValuePortfolio ChangePosition ChangeAvg Buy PriceCurrent Price
Ken GriffinCitadel Advisors
$15M483.7k shares
AddQ1 2026
$9.7M
$31.50
$33.54
Paul Tudor Jones IITudor Investment
$942k29.9k shares
AddQ1 2026
$70k
$31.50
$33.54
Ken GriffinCitadel Advisors
$5.5M223.3k shares
AddQ4 2025
$4.1M
$24.82
$33.54
Ken GriffinCitadel Advisors
$5.5M223.3k shares
ExitQ4 2025
$1.4M
$24.82
$33.54
Paul Tudor Jones IITudor Investment
$-546.2K
ExitQ3 2025
$546k
--
$33.54
Paul Tudor Jones IITudor Investment
$-546.2K
ExitQ3 2025
$546k
--
$33.54

News

seekingalpha.comEdgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancementseekingalpha.comJun 4prnewswire.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesprnewswire.comJun 3zacks.comEdgewise Therapeutics Stock Hits Record High on $2.65B Servier Dealzacks.comJun 2reuters.comEdgewise to sell muscle dystrophy business to Servier for up to $2.65 billionreuters.comJun 1prnewswire.comEdgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipelineprnewswire.comJun 1